Log in to save to my catalogue

Post-Progression Treatments after Palbociclib plus Endocrine Therapy in HR+/HER2– Metastatic Breast...

Post-Progression Treatments after Palbociclib plus Endocrine Therapy in HR+/HER2– Metastatic Breast...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmed_primary_34875670

Post-Progression Treatments after Palbociclib plus Endocrine Therapy in HR+/HER2– Metastatic Breast Cancer Patients: What Is the Better Choice?

About this item

Publication information

Publisher

Switzerland

More information

Scope and Contents

Contents

Background: To date, a consensus has not yet been reached about the therapy sequence after disease progression (PD) on CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer (MBC). Objectives: The present study assesses, in a real-world setting, the activity of different subsequent therapies in patients who experienced a PD on palboc...

Alternative Titles

Full title

Post-Progression Treatments after Palbociclib plus Endocrine Therapy in HR+/HER2– Metastatic Breast Cancer Patients: What Is the Better Choice?

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmed_primary_34875670

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmed_primary_34875670

Other Identifiers

ISSN

0030-2414

E-ISSN

1423-0232

DOI

10.1159/000521252

How to access this item